Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ENSC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsEnsysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026
Filed July 15, 2026 · Period ending July 15, 2026 · ~1 min read
Key Changes
-
medium
Chief Operating Officer Jeffrey Millard resigned effective July 10, 2026; no reason disclosed and no successor named.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Ensysce Biosciences disclosed that Chief Operating Officer Jeffrey Millard resigned effective July 10, 2026. The filing does not provide a reason for the departure or indicate whether the company has identified a successor. For a clinical-stage biotech, the COO typically oversees operational execution including clinical trial management and manufacturing readiness.
The absence of disclosed circumstances or a transition plan leaves investors without visibility into whether this reflects a strategic disagreement, personal reasons, or operational challenges. Retail holders should monitor upcoming filings and earnings calls for commentary on how the company will manage COO responsibilities and whether leadership continuity affects development timelines.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 15, 2026 · How we verify